In a world of rising clinical development costs, tighter regulatory scrutiny and continued pressures to accelerate timelines without compromising scientific rigor, leaders across clinical development face unprecedented challenges. Success hinges on making high-stakes decisions in a complex environment.
Biostatistics isn’t just about the reporting and analysis of clinical trials. It’s about enabling informed quantitative decision-making under uncertainty and building clinical development plans that are fit-for-purpose and answer critical questions.
In large pharma, biostatisticians are deeply embedded in clinical development strategy and execution from the outset.
Smaller organizations can achieve the same strategic advantages by asking the right questions of their biostatistics partner. Here’s how to unlock that potential:
1. Which clinical development options should we explore?
Biostatisticians bring a data-driven lens to asset strategy, helping teams evaluate multiple development pathways through modelling, simulation, and benefit-risk analysis. By integrating early efficacy signals and expert knowledge, competitive landscape insights, and regulatory precedents, biostatisticians can guide sponsors by providing quantitative comparisons and trade-offs between different paths. This strategic input ensures that plans are not only scientifically sound but also aligned with long-term company goals.
2. How can we best leverage historical data and real-world evidence in our plans?
Historical clinical trial data and real-world evidence (RWE) are powerful resources when used correctly. Biostatisticians assess the relevance, quality, and comparability of these data sources to inform study designs and clinical programs. This data can be used to refine study protocols through optimizing eligibility criteria, identification of sub populations, and selection of valid endpoints. More formally, these data can inform sample size and power calculations to enhance the likelihood of trial success, or be integrated into external control arms or Bayesian analyses to reduce required sample sizes, ultimately reducing costs and timelines. Technical expertise ensures that these data are integrated in statistically robust ways that enhance credibility with regulators and accelerate decision-making.
3. Can we utilize adaptive or other innovative trial designs to accelerate development?
Adaptive designs, platform and basket trials, and Bayesian methods can deliver significant flexibility, improve efficiency, and accelerate clinical development to get medicines to patients faster. However, they require careful planning and robust statistical oversight and might not be applicable in all situations. Biostatisticians can explore different options and evaluate the feasibility and regulatory acceptability of these innovative designs compared to traditional approaches. By presenting operating characteristics, quantifying risks and estimating the likelihood of success, they enable decision-makers to clearly understand the implications of each option to make informed, strategic decisions.
4. What are the main risks in our clinical development plans and how can we mitigate them?
Clinical development is fraught with risk. This may be recruitment challenges, patient retention, data collection and validation issues or evolving regulatory requirements. These risks can derail timelines, inflate costs, and compromise the credibility of your evidence package. Biostatisticians play a critical role in proactively identifying and quantifying both statistical and operational risks through scenario modeling. By collaborating cross-functionally, they help design mitigation strategies such as interim analyses, contingency plans, and monitoring frameworks that safeguard trial integrity and ensure strategic agility.
5. How can we obtain the most robust evidence to satisfy future investors and partners?
Robust evidence goes beyond statistical significance. It must demonstrate clear clinical relevance and show meaningful benefit for patients. It should be commercially viable, supporting market access and payer confidence, and reproducible across diverse populations and settings to withstand scrutiny. Most importantly, it needs to be aligned with stakeholder expectations, from regulators and health technology assessors to investors and strategic partners, ensuring that the data tells a compelling story of value and differentiation. Biostatisticians help consider all these aspects and quantify how the clinical programs and evidence plans are de-risked at each stage, giving investors and partners confidence in a program’s potential.
Broaden the biostatistics conversation
By asking broader strategic questions rather than narrow technical ones, sponsors can get more value from their biostatisticians. These experts are critical partners in shaping development strategy, optimizing trial design, and anticipating regulatory and operational challenges. They also help define the right questions from the outset, which not only leads to optimally designed studies, but it ensures the right data and evidence is collected to enable relevant insights and smarter decisions. Engaging them early and meaningfully can help avoid costly mistakes and streamline clinical execution, while building a more compelling narrative for regulators, partners, and investors. Ultimately, this approach leads to smarter decisions, faster progress, and stronger positioning in a competitive landscape without compromising quality or integrity.
